<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /opt/grobid/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">The ever-growing case for clozapine in the treatment of schizophrenia: an obligation for psychiatrists and psychiatry</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">A</forename><surname>Bittner</surname></persName>
							<email>robert.bittner@med.uni-frankfurt.de</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Psychiatry</orgName>
								<orgName type="department" key="dep2">Psychosomatic Medicine, and Psychotherapy</orgName>
								<orgName type="institution" key="instit1">University Hospital Frankfurt</orgName>
								<orgName type="institution" key="instit2">Goethe University</orgName>
								<address>
									<settlement>Frankfurt</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Ernst Str√ºngmann Institute for Neuroscience (ESI) in Cooperation with Max Planck Society</orgName>
								<address>
									<settlement>Frankfurt am Main</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Corresponding author. Department of Psychiatry, Psychosomatic Medicine and Psychotherapy</orgName>
								<orgName type="institution" key="instit1">University Hospital Frankfurt</orgName>
								<orgName type="institution" key="instit2">Goethe University</orgName>
								<address>
									<addrLine>Heinrich-Hoffmann-Str. 10</addrLine>
									<postCode>D-60528</postCode>
									<settlement>Frankfurt am Main</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andreas</forename><surname>Reif</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Psychiatry</orgName>
								<orgName type="department" key="dep2">Psychosomatic Medicine, and Psychotherapy</orgName>
								<orgName type="institution" key="instit1">University Hospital Frankfurt</orgName>
								<orgName type="institution" key="instit2">Goethe University</orgName>
								<address>
									<settlement>Frankfurt</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mishal</forename><surname>Qubad</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Psychiatry</orgName>
								<orgName type="department" key="dep2">Psychosomatic Medicine, and Psychotherapy</orgName>
								<orgName type="institution" key="instit1">University Hospital Frankfurt</orgName>
								<orgName type="institution" key="instit2">Goethe University</orgName>
								<address>
									<settlement>Frankfurt</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">The ever-growing case for clozapine in the treatment of schizophrenia: an obligation for psychiatrists and psychiatry</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="DOI">10.31234/osf.io/ruzga</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.1" ident="GROBID" when="2025-06-29T13:50+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Schizophrenia</term>
					<term>clozapine</term>
					<term>treatment resistance</term>
					<term>mortality rates</term>
					<term>shared decisionmaking</term>
				</keywords>
			</textClass>
			<abstract>
				<p>Clozapine remains the gold standard for treatment-resistant schizophrenia (TRS). Although the evidence base for its wide-ranging, unique efficacy continues to expand, clozapine remains alarmingly underutilized in industrialized countries. Analyzing the causes and consequences of this problem is crucial for substantially improving the quality of care for TRS patients. Recent findings: Clozapine is the most effective antipsychotic for reducing all-cause mortality in TRS. In most cases, treatment resistance emerges during the first psychotic episode. Delaying clozapine treatment has a negative impact on long-term outcome. Patients&apos; experience with clozapine treatment is largely positive despite a comparatively high rate of side effects. Patients prefer clozapine, while psychiatrists regard it as a burden due to concerns regarding safety and side effect management. Shared decision-making (SDM), which increases the likelihood of a clozapine recommendation, is not routinely used, possibly due to stigmatization of TRS patients.</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p>Like no other medication, clozapine epitomizes two fundamental challenges in the pharmacotherapy of schizophrenia: a dearth of innovation <ref type="bibr" target="#b0">1</ref> , and insufficient implementation of established treatments 2**, <ref type="bibr" target="#b4">3</ref> . Clozapine remains the most effective antipsychotic and the only drug approved for treatment-resistant schizophrenia (TRS) not least, because the neurobiological underpinnings of its unique efficacy continue to elude researchers 4* . Consequently, clozapine should be widely used for TRS but also for certain non-TRS patients. Yet, only a fraction of suitable patients actually receives clozapine <ref type="bibr" target="#b7">5</ref> often years after treatment resistance becomes evident 6**, <ref type="bibr" target="#b10">7,</ref><ref type="bibr" target="#b11">8</ref> .</p><p>In this review, we contrast the literature advocating its safe and effective use with current evidence regarding the causes and consequences of clozapine underutilization. We highlight those issues we deem most relevant to remedy this crucial issue. Additionally, we discuss ongoing efforts to improve treatment efficacy and safety.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CLINICAL EFFECTS</head><p>Clozapine has a singular impact of on key mediators of poor illness outcome. It is the most effective drug for improving positive symptoms and global psychopathology both in the most severely ill <ref type="bibr" target="#b12">9</ref> and in the full spectrum of patients <ref type="bibr" target="#b14">10</ref> . Its effects on negative and depressive symptoms rank among the best of all antipsychotics <ref type="bibr" target="#b14">10</ref> .</p><p>Clozapine shows superior anti-suicidal efficacy 11* and the largest reduction of aggression <ref type="bibr" target="#b18">12</ref> . It also decreases the risk for new and persisting co-morbid substance use disorders (SUDs) 13** . Additional long-term benefits include improved treatment adherence 14** and reduced rehospitalization rates <ref type="bibr" target="#b23">15</ref> .</p><p>Bittner et al. -The case for clozapine treatment of schizophrenia 5</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MORTALITY-REDUCING EFFECTS</head><p>Most importantly, clozapine is also particularly relevant for addressing the substantial mortality gap of schizophrenia. Patients die approximately 15 years prematurely 16** , largely due to high rates of somatic comorbidities <ref type="bibr" target="#b26">17</ref> . For TRS, clozapine shows a greater reduction of all-cause mortality than any other antipsychotic 16** . Across all patients, only second-generation long-acting injectable antipsychotics (SGA-LAIs) match this effect 16** , which likely reflects the convergence of clozapine's wideranging clinical benefits including ameliorating the substantial mortality risks associated with SUDs <ref type="bibr" target="#b27">18</ref> . Despite relatively high rates of metabolic side effects, clozapine's positive impact on cardiovascular mortality is comparable to other SGAs <ref type="bibr" target="#b28">19</ref> , not least because it induces the largest improvements in adherence to treatments for somatic disorders 20** . This makes clozapine the most effective psychopharmacotherapy for reducing mortality in TRSa long established treatment priority in other medical disciplines, which psychiatry urgently needs to adopt.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>VISIBLE AND INVISIBLE BENEFITS</head><p>Such an approach would also facilitate appreciation of clozapine's vital long-term benefits. While its psychopathological effects can be remarkable, improved treatment adherence, lower rates of rehospitalization and SUDs, as well as reduced suicide and all-cause mortality rates remain underrecognized <ref type="figure" target="#fig_3">(Figure 1</ref>). Yet, they are central for its literally life-changing impact on many patients and should substantially influence clinical decision-making.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>TRS EPIDEMIOLOGY AND NEUROBIOLOGY</head><p>Although clozapine can confer important benefits to non-TRS patients, its most important indication remains TRS, which encompasses approximately a third of all Bittner et al. -The case for clozapine treatment of schizophrenia 6 patients 21, <ref type="bibr" target="#b33">22</ref> . TRS contributes the most to the overall costs of schizophrenia 21 , making clozapine treatment particularly cost-effective <ref type="bibr">23,24*</ref> . Importantly, treatment resistance is characterized by a predominantly early onset ( <ref type="figure" target="#fig_4">Figure 2)</ref>. A quarter of patients with first-episode psychosis (FEP) already fulfill TRS criteria 25** , making clozapine an important element of FEP treatment algorithms. This may be counterintuitive, given that most clozapine trials studied chronically ill patients 26 .</p><p>Yet, this notion is in keeping with the neurobiology of TRS 22,27,28**,29** . Primary treatment resistance at illness onset appears to emerge directly from the pathophysiology of schizophrenia <ref type="bibr" target="#b33">22,</ref><ref type="bibr" target="#b45">30</ref> and shows little responsivity to standard antipsychotic treatment <ref type="bibr" target="#b45">30,</ref><ref type="bibr" target="#b46">31</ref> . Clozapine appears to uniquely improve some of the implicated neurobiological abnormalities including glutamatergic and GABAergic neurotransmission 28**,32 .</p><p>Conversely, treatment resistance emerging at subsequent illness stages is more likely attributable to secondary factors including insufficient treatment adherence and dopaminergic supersensitivity <ref type="bibr" target="#b33">22</ref> . Although clozapine is also effective in secondary treatment resistance, this suggests a unique neurobiological rationale for switching to clozapine in first-episode patients with primary treatment resistance.</p><p>Current findings also imply that some secondary forms of treatment resistance might be preventable. Interestingly, there is tentative evidence that SGA-LAIsthe most effective first-line treatment regarding treatment adherence and relapse prevention <ref type="bibr" target="#b48">33</ref> might delay the onset of TRS by 15 months 34 . Unfortunately, this opportunity is presently squandered because of widespread underutilization of SGA-LAIs <ref type="bibr" target="#b48">33</ref> .</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>SAFETY AND RESPONSE OPTIMIZATION</head><p>To enhance patients' benefits, optimizing clozapine safety and efficacy is essential.</p><p>Bittner et al. -The case for clozapine treatment of schizophrenia Proactive side effect detection and management constitute crucial skills, which can alleviate common concerns regarding neutropenia, myocarditis, weight gain and metabolic syndrome among others. This has prompted detailed guidelines 35**,36*,37** , which make the safe use of clozapine eminently feasible and help to minimize allcause discontinuation. The notable success rate for re-challenges after neutropenia and myocarditis of approximately sixty percent <ref type="bibr" target="#b55">38,</ref><ref type="bibr" target="#b56">39</ref> underscores the need for rechallenge consensus protocols based on more systematic studies.</p><p>Therapeutic drug monitoring (TMD) is critical for ensuring optimal plasma levels (350 to 600 ng/ml) <ref type="bibr">40</ref> . While existing studies estimate the mean clozapine response rate at 40 percent <ref type="bibr" target="#b59">41</ref> , only a fraction of them utilized TDM. Observational data have also demonstrated considerable underuse of TDM and plasma levels outside the recommended range in many monitored patients 42* . Implementing the routine use of TDM could raise response rates and patient safety substantially. However, ensuring a timely initiation of clozapine probably remains the most important and disregarded optimization strategy.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>THE DELAY IN INITIATING CLOZAPINE</head><p>The delay in initiating clozapine (DIC) after establishing treatment resistance, which is estimated at around 5 to 7 years, has important prognostic value 6**, <ref type="bibr" target="#b10">7,</ref><ref type="bibr" target="#b11">8,</ref><ref type="bibr">21</ref> . After a DIC of more than 2-4 years response rates can decline considerably 6** , while a short DIC is associated with response rates of up to 80 percent <ref type="bibr" target="#b61">43</ref> . The impact of the DIC mirrors the well-established prognostic value of the duration of untreated psychosis (DUP) <ref type="bibr" target="#b62">44</ref> , which also constitutes a risk factor for treatment resistance <ref type="bibr" target="#b64">45,</ref><ref type="bibr" target="#b65">46</ref> . These findings hint at possible neurobiological connections between the sequelae of a long DUP and a long DIC. Furthermore, they highlight the potential of early intervention services (EIS) for detecting and managing treatment resistance <ref type="bibr" target="#b66">47</ref> . Their success in Bittner et al. -The case for clozapine treatment of schizophrenia 8 lowering the DUP is the main raison d'√™tre for (EIS) <ref type="bibr" target="#b62">44</ref> . Based on the predominantly early emergence of treatment resistance 25** and recent findings demonstrating that EIS can reduce the DIC <ref type="bibr" target="#b64">45</ref> , strategies for detecting treatment resistance should become a standard element of EIS. The observation that EIS might have little effect on the prevalence of treatment resistance <ref type="bibr" target="#b64">45</ref> does not argue against this strategy, but rather supports the notion that primary TRS represents a distinct group of schizophrenia biotypes unresponsive to non-clozapine antipsychotics <ref type="bibr" target="#b62">44</ref> .</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CLOZAPINE UNDERUTILIZATION</head><p>Despite the overwhelmingly favorable evidence, which is reflected in unanimous </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ATTITUDE OF PSYCHIATRISTS TOWARDS CLOZAPINE</head><p>Clozapine underutilization appears to be attributable particularly to clinician's concerns regarding potential side-effects, especially an overestimation of the risks associated with blood dyscrasia 49*,52,54,55 and a lack of resources for blood sampling and other monitoring procedures <ref type="bibr" target="#b74">52</ref> . Clinician's apprehension appears to be further amplified by limited knowledge regarding treatment algorithms and side effect management <ref type="bibr" target="#b74">52,</ref><ref type="bibr" target="#b76">54,</ref><ref type="bibr" target="#b79">56,</ref><ref type="bibr" target="#b80">57</ref> . Importantly, this might result in a vicious cycle of less prescription leading to less expertise <ref type="bibr" target="#b80">57</ref> . Furthermore, psychiatrists predominantly presume that patients would not accept clozapine and its monitoring requirements 53* , regard clozapine treatment as a burden for both patients and prescribers 58,59** , and assume that patients receiving clozapine are less satisfied <ref type="bibr" target="#b84">60</ref> .</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>THE PATIENTS' PERSPECTIVE</head><p>Conversely, the majority of patients consistently reports a high degree of satisfaction with clozapine alongside noticeable symptom improvements and a clear preference over previous medications 53*,55,59** . The less common negative experiences center on blood tests and common side effects, especially hypersalivation and weight gain 59** . The clear improvements in treatment adherence after switching to clozapine despite its side effects and monitoring requirements 9 underline the broad benefits experienced by patients, which might motivate them to tolerate some drawbacks.</p><p>Moreover, the reduced rate of polypharmacy promoted by clozapine treatment 61** might also diminish differences in the side effect burden and contribute to patients' preference.</p><p>Bittner et al. -The case for clozapine treatment of schizophrenia</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>10</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>SHARED DECISION-MAKING</head><p>Overall, current evidence confirms "prescriber fear" <ref type="bibr" target="#b79">56</ref> the reluctance of psychiatrists to recommend clozapine out of concern for the safety and complexity of its useas a central cause of clozapine underutilization. The striking differences between patient and prescriber attitudes forms one of the most crucial barriers for adequate clozapine use. Psychiatrists might refrain from offering every eligible patient the opportunity of a clozapine trial based on the false assumption that most patients will decline <ref type="bibr" target="#b87">62</ref> . Importantly, by not even seriously discussing clozapine, clinicians essentially deny many patients their best chance at substantial clinical improvement <ref type="bibr" target="#b61">43</ref> . However, patients have a right to receive the best treatment available in a safe and timely manner <ref type="bibr" target="#b61">43</ref> , and psychiatrists have a clear ethical and medical obligation not to deny them this right.</p><p>Accordingly, psychiatrists must not make the potentially life-changing decision regarding clozapine initiation for their patients 63** . This is particularly important given thaton average -patients' attitudes and preferences align with both the evidence and guideline recommendations, whereas psychiatrists' attitudes and actions do not.</p><p>Hence, even many severely ill patients with TRS retain sufficient capacity to make informed choices to their benefit. This underscores the need to consistently use shared decision-making (SDM). encouraged to make a more informed decision after three months of treatment <ref type="bibr" target="#b100">72</ref> based on their personally experienced benefits and side effects. Clinician should also be prepared to make repeated offers, if necessary 3 .</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BARRIERS TO SHARED DECISION-MAKING</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>POSSIBLE SOLUTIONS</head><p>Addressing clozapine underutilization rates requires overcoming prescriber-and patient-related as well as healthcare system-related barriers 50* . Although prescriberrelated barriers appear to be the most crucial, overcoming other hurdles remains essential. Specialized TRS treatment teams <ref type="bibr" target="#b101">73</ref> ideally in combination with national networks of excellence <ref type="bibr" target="#b102">74</ref> can comprehensively address some of the most pressing issues. This includes educating residents, caregivers and families 53* by disseminating the knowledge and skills required for successful TRS detection and clozapine use ( <ref type="figure" target="#fig_5">Figure 3</ref>) <ref type="bibr" target="#b78">55,</ref><ref type="bibr" target="#b102">74,</ref><ref type="bibr" target="#b103">75</ref> . They could also promote shared decision-making <ref type="bibr" target="#b74">52</ref> , provide access to interdisciplinary teams for side effect management 53*,55,76 and issue mandatory clozapine certifications to formalize medical training <ref type="bibr" target="#b80">57</ref> . Point-of-care devices for full blood cell counts and TDM have the potential to greatly simplify monitoring requirements 50*, <ref type="bibr" target="#b74">52,</ref><ref type="bibr" target="#b78">55,</ref><ref type="bibr" target="#b102">74</ref> . Responsibly easing policies such as restrictions for re-challenging patients after mild forms of neutropenia <ref type="bibr" target="#b55">38</ref> and blood monitoring requirements after the initial year of treatment <ref type="bibr" target="#b105">77</ref> should also increase clozapine use.</p><p>Finally, given that the potentially high response rates of clozapine clearly invalidate the term 'treatment resistant' for many patients, characterizing them as 'clozapineresponsive' is warranted from both a clinical and neurobiological perspective. This might also help to reduce stigma and therapeutic nihilism by shifting the focus to the essential question, whether a particular patient benefits from clozapine. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>KEY POINTS</head><p>‚Ä¢ For treatment resistant schizophrenia, clozapine shows superior efficacy regarding global psychopathology, suicidality, aggression, substance use, treatment adherence and rehospitalization rates.</p><p>‚Ä¢ For treatment resistant schizophrenia, clozapine shows the strongest reduction in all-cause mortality and the biggest improvement in treatment adherence for cardiovascular and metabolic disorders.</p><p>‚Ä¢ The delay in initiating clozapine in treatment-resistant patients has clear prognostic value.</p><p>‚Ä¢ Prescriber-related factors appear to be the largest contributor to clozapine underutilization, while patient's acceptance and satisfaction is high.</p><p>‚Ä¢ Consistent use of shared decision-making is key for addressing clozapine underutilization.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>FIGURES</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Figure 1</head><p>Bittner et al. -The case for clozapine treatment of schizophrenia   </p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc>guideline recommendations 48** , clozapine remains severely underused across industrialized countries 5,49*,50* with underutilization apparently most pronounced in female TRS patients 51* . There are notable differences between and within countries, which might offer important clues for the underlying causes. For instance, data from the United States indicate that in a sizeable number of states only a minority of eligible individuals receive clozapine 52,53* . Similarly, in the United Kingdom, an estimated one third of TRS patients in the UK are treated clozapine 54 , whereas clozapine prescription rates Finland in are more than twice as high 54 . Instead of clozapine, patients are often treated with considerably less effective approaches including polypharmacy lacking sufficient evidence 21,43 . Ineffective treatment considerably increases the disease burden for patients, which is caused by persistent clinical symptoms, the overall functional impairment as well as the pessimism and therapeutic nihilism widely prevalent within treatment teams 21 . Bittner et al. -The case for clozapine treatment of schizophrenia</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc>SDM represents the gold standard of patient-clinician interaction across health systems 64* . The feasibility of integrating SDM in the treatment of schizophrenia and its positive impact on outcomes is well established64*,65  . Most importantly, there is evidence that using SDM and emphasizing the patient's perspective and patientspecific clinical information strongly increases the likelihood of psychiatric trainees to recommend clozapine<ref type="bibr" target="#b93">66</ref> . This indicates that focusing on the patients' needs and their potential benefits is a crucial catalyst of clozapine use. SDM is well suited to facilitate such a change in perspective in psychiatrists 67 , and allow patients' preference sufficient influence on treatment decisions 64* . Its potential for addressing clozapine underutilization underscores the urgent need for the development of standardized SDM tools their incorporation into routine clinical practice and training 64* .One potential barrier for SDM<ref type="bibr" target="#b96">68</ref> may be particularly pertinent to TRS patients. Their high levels of cognitive impairment 21,69 may raise doubts regarding their cognitive capacity. However, concluding that they are too impaired to partake in SDM constitutes a form of stigmatization 64* . The consequences of treatment resistance including persistent positive symptoms, aggression, and SUDs likely also contribute to high levels of stigma. High levels of stigma among patients or their caregivers are indeed associated with more paternalistic decision-making and less SDM 70 . Currently, the exact role of stigma as an obstacle for clozapine treatment remains unclear. However, there is unequivocal, disconcerting evidence that among mental health professionals (MHP) schizophrenia is the most stigmatized mental disorder 71 . The negative consequences for the level of care provided 64* highlight the urgent need for systematic efforts to reduce stigmatization of schizophrenia among MHP, which should also have a positive impact on SDM and clozapine use. OFFERING CLOZAPINE Decisions regarding clozapine should be informed by its unique efficacy, the full extent of its benefits, their comparatively late onset, the high patient satisfaction as well as the good feasibility of side effect monitoring and management. For patients with limited illness insight, emphasizing effects on rehospitalization rates, SUDs and mortality might be particularly valuable. Moreover, ambivalent patients should be Bittner et al. -The case for clozapine treatment of schizophrenia 12</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>13 OUTLOOK</head><label>13</label><figDesc>Bittner et al. -The case for clozapine treatment of schizophrenia Currently, personalized medicine approaches aim to optimize clozapine treatment further. These include developing predictive markers for treatment resistance 28**,78**,79** , clozapine response 4*,80+,81 , and side effectsespecially agranulocytosis and myocarditis 82*,83* as well as individualizing dosing and switching regimes 84*,85* . Moreover, studies designed to conclusively determine whether clozapine might have disease-modifying properties and slow illness progression when used very early 4* are urgently needed. Finally, elucidating the neurobiological mechanisms of clozapine remains a promising strategy for the discovery of more effective compounds 4* . CONCLUSION All evidence indicates that for many patients, clozapine remains the only effective antipsychotic available. In our view, its unrivalled value constitutes an obligation for individual psychiatrists and our field as a whole to make clozapine accessible to eligible patients as widely, swiftly, safely and effectively as possible. All available evidence indicates that this would bring immense benefits to a group of people that is among the most vulnerable in all of psychiatry 21 .</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 1 -</head><label>1</label><figDesc>Visibility of clozapine-associated benefitsClinical effects of clozapine can be subdivided in clearly evident short-term and, less prominent long-term effects reminiscent of an iceberg model. Positive, negative, and depressive symptoms rank among those whose decline is most visible. Conversely, reduction of all-cause mortality might be practically invisible and might therefore be disregarded.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 2 -</head><label>2</label><figDesc>Treatment resistant schizophrenia Minimal criteria for the diagnosis of TRS in accordance with the TRRIP working group. Overall, TRS diagnosis necessitates non-response to non-clozapine antipsychotics dispite confirmed correct diagnosis, adequate antipsychotic treatment, and exclusion of pseudoresistance. Current data indicate that approximately one fourth of FEP patients and approximately one third of all SZ patients meet criteria for TRS. For these patients, treatment with clozapine can substantially reduce the burden illness. TRS = treatment-resistant schizophrenia; TRRIP = Treatment Response and Resistance in Psychosis Working Group; FEP = first-episode psychosis, PSZ = people with schizophrenia.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Figure 3 -</head><label>3</label><figDesc>Relevant factors for addressing clozapine underutilization Factors encouraging clozapine utilization can be subdivided into clinical key skills and structural changes. A) Promoting clinical key skills address clinical knowledge regarding safe and effective clozapine use. This also requires implementation of standardized procedures for shared decision making. B) Structural changes: national networks of excellence formed by specialized TRS units can facilitate clozapine use</figDesc></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">through a variety of activities including adjusting monitoring protocols and destigmatization of PSZ.</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGEMENTS</head><p>The authors would like to thank Manon Perret for helpful comments on the manuscript and G. Herzog for help with the figures.</p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>AUTHOR CONTRIBUTIONS</head><p>All authors made substantial contributions to the conception and design of the work.</p><p>RAB and MQ undertook the literature searches and wrote the first draft of the manuscript. All authors contributed to and revised the manuscript. All authors read and approved the final manuscript.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>FINANCIAL SUPPORT AND SPONSORSHIP</head><p>None.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONFLICTS OF INTEREST</head><p>There are no conflicts of interest.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">L</forename><surname>Spark</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Fornito</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">J</forename><surname>Langmead</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41398-022-01904-2</idno>
	</analytic>
	<monogr>
		<title level="j">Translational Psychiatry</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">147</biblScope>
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title level="m" type="main">Controversies Surrounding the Use of Long-Acting</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Kane</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">P</forename><surname>Mcevoy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">U</forename><surname>Correll</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia</title>
		<idno type="DOI">10.1007/s40263-021-00861-6</idno>
	</analytic>
	<monogr>
		<title level="j">CNS Drugs</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="1189" to="1205" />
			<date type="published" when="2021" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<title level="m" type="main">This review discusses controversies associated with LAIs which constitute a barrier for successful treatment. Addressing these barriers and promoting widespread use of LAIs might also reduce TRS rates due to improved treatment adherence</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">*</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">How and when to use clozapine</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Rubio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Kane</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Psychiatrica Scandinavica</title>
		<imprint>
			<date type="published" when="2020" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title/>
		<idno type="DOI">10.1111/acps.13111</idno>
		<ptr target="https://doi.org/10.1111/acps.13111" />
		<imprint>
			<biblScope unit="page" from="178" to="189" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Clozapine&apos;s multiple cellular mechanisms: What do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>De Bartolomeis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Vellucci</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Barone</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol Ther</title>
		<imprint>
			<date type="published" when="2022" />
		</imprint>
	</monogr>
	<note>236: 108236. 20220625. DOI: 10.1016/j.pharmthera.2022.108236 * A summary of the current knowledge regarding the pleitropic effects of clozapine</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">International trends in clozapine use: a study in 17 countries</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">J</forename><surname>Bachmann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Aagaard</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Bernardo</surname></persName>
		</author>
		<idno type="DOI">10.1111/acps.12742</idno>
		<ptr target="https://doi.org/10.1111/acps.12742" />
	</analytic>
	<monogr>
		<title level="j">Acta Psychiatrica Scandinavica</title>
		<imprint>
			<biblScope unit="volume">136</biblScope>
			<biblScope unit="page" from="37" to="51" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Duration of prior psychotic illness and clozapine response: a retrospective observational study using electronic health records. Therapeutic Advances in</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Upthegrove</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">J</forename><surname>Price</surname></persName>
		</author>
		<idno type="DOI">10.1177/20451253221103353</idno>
	</analytic>
	<monogr>
		<title level="j">Psychopharmacology</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">20451253221103353</biblScope>
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<monogr>
		<title level="m" type="main">This study highlights the relevance of timely clozapine initiation in TRS. Delaying clozapine treatment can considerably reduce its efficacy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">*</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Clozapine response trajectories and predictors of nonresponse in treatment-resistant schizophrenia: a chart review study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Iwata</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">E</forename><surname>Brown</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00406-019-01053-6</idno>
	</analytic>
	<monogr>
		<title level="j">European Archives of Psychiatry and Clinical Neuroscience</title>
		<imprint>
			<biblScope unit="volume">270</biblScope>
			<biblScope unit="page" from="11" to="22" />
			<date type="published" when="2020" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Correlation between delay in initiating clozapine and symptomatic improvement</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Yada</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yoshimura</forename><forename type="middle">B</forename><surname>Kishi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.schres.2015.07.045</idno>
	</analytic>
	<monogr>
		<title level="j">Schizophr Res</title>
		<imprint>
			<biblScope unit="volume">168</biblScope>
			<biblScope unit="page" from="585" to="586" />
			<date type="published" when="2015-08-05" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<monogr>
		<title level="m" type="main">Association With Hospitalization and All-Cause</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Masuda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Misawa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Takase</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics: A Systematic Review and Meta-analysis of Cohort Studies</title>
		<idno type="DOI">10.1001/jamapsychiatry.2019.1702</idno>
	</analytic>
	<monogr>
		<title level="j">JAMA psychiatry</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="1052" to="1062" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Huhn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Nikolakopoulou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Schneider-Thoma</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">394</biblScope>
			<biblScope unit="page" from="939" to="951" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<monogr>
		<title/>
		<idno type="DOI">10.1016/S0140-6736(19)31135-3</idno>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Prevention of suicide by clozapine in mental disorders: systematic review</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Masdrakis</forename><surname>Vg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">S</forename><surname>Baldwin</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.euroneuro.2022.12.011</idno>
		<ptr target="https://doi.org/10.1016/j.euroneuro.2022.12.011" />
	</analytic>
	<monogr>
		<title level="j">European Neuropsychopharmacology</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="4" to="23" />
			<date type="published" when="2023" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<monogr>
		<title level="m" type="main">* A detailed summary of the superior anti-suicidal effects of clozapine</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Efficacy of typical and atypical antipsychotic medication on hostility in patients with psychosis-spectrum disorders: a review and meta-analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mdm</forename><surname>Faay</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Czobor</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Iec</forename><surname>Sommer</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41386-018-0161-2</idno>
	</analytic>
	<monogr>
		<title level="j">Neuropsychopharmacology</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="2340" to="2349" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<monogr>
		<title level="m" type="main">Associations between antipsychotic use, substance use and relapse risk in patients with schizophrenia: real-world evidence from two national cohorts</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>L√§hteenvuo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">J</forename><surname>Luykx</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Taipale</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<idno type="DOI">10.1192/bjp.2022.117</idno>
	</analytic>
	<monogr>
		<title level="m">** Based on real-world data, this study highlights the considerable impact of clozapine on SUDs</title>
		<imprint>
			<biblScope unit="volume">2022</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<monogr>
		<title level="m" type="main">Clozapine not only reduces risk of developing SUDs but also reduces relapse rates among patients with existing co-morbid SUDs</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Association between previous and future antipsychotic adherence in patients initiating clozapine: real-world observational study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Brodeur</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Courteau</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Vanasse</surname></persName>
		</author>
		<idno type="DOI">10.1192/bjp.2022.1</idno>
	</analytic>
	<monogr>
		<title level="j">The British Journal of Psychiatry</title>
		<imprint>
			<biblScope unit="volume">220</biblScope>
			<date type="published" when="2022" />
		</imprint>
	</monogr>
	<note>** This study evaluates the impact of clozapine on treatment adherence in a cohort of more than 3000 patien. Clozapine leads to a clear improvement in treatment adherence</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Tiihonen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Mittendorfer-Rutz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Majak</surname></persName>
		</author>
		<idno type="DOI">10.1001/jamapsychiatry.2017.1322</idno>
	</analytic>
	<monogr>
		<title level="j">JAMA Psychiatry</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page" from="686" to="693" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">U</forename><surname>Correll</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Solmi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Croatto</surname></persName>
		</author>
		<idno type="DOI">10.1002/wps.20994</idno>
		<ptr target="https://doi.org/10.1002/wps.20994" />
	</analytic>
	<monogr>
		<title level="j">World Psychiatry</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="248" to="271" />
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<monogr>
		<title level="m" type="main">This study provides the best evidence yet that treatment with SGA-LAIs or clozapine considerably reduce all-cause mortality in schizophrenia. For TRS, clozapine has the strongest impact on all-cause and suicide-related mortality</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">*</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Excess early mortality in schizophrenia</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">M</forename><surname>Laursen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Nordentoft</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">B</forename><surname>Mortensen</surname></persName>
		</author>
		<idno type="DOI">10.1146/annurev-clinpsy-032813-153657</idno>
	</analytic>
	<monogr>
		<title level="j">Annu Rev Clin Psychol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Morbidity and mortality in schizophrenia with comorbid substance use disorders</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>L√§hteenvuo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Batalla</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">J</forename><surname>Luykx</surname></persName>
		</author>
		<idno type="DOI">10.1111/acps.13291</idno>
		<ptr target="https://doi.org/10.1111/acps.13291" />
	</analytic>
	<monogr>
		<title level="j">Acta Psychiatrica Scandinavica</title>
		<imprint>
			<biblScope unit="volume">144</biblScope>
			<biblScope unit="page" from="42" to="49" />
			<date type="published" when="2021" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Taipale</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Tanskanen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Meht√§l√§</surname></persName>
		</author>
		<idno type="DOI">10.1002/wps.20699</idno>
		<ptr target="https://doi.org/10.1002/wps.20699" />
	</analytic>
	<monogr>
		<title level="j">World Psychiatry</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="61" to="68" />
			<date type="published" when="2020" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Solmi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Tiihonen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>L√§hteenvuo</surname></persName>
		</author>
		<idno type="DOI">10.1093/schbul/sbab087</idno>
		<ptr target="DOI:10.1093/schbul/sbab087" />
	</analytic>
	<monogr>
		<title level="j">Schizophrenia Bulletin</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="166" to="175" />
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<monogr>
		<title level="m">** This study investigates the impact of antipsychotic medication on treatment adherence for statins, anti-diabetics, antihypertensives, and beta-blockers</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<monogr>
		<title level="m" type="main">Overall, clozapine leads to the biggest improvement in treatment adherence</title>
		<imprint/>
	</monogr>
	<note>nb 21</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Kane</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><surname>Agid</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">L</forename><surname>Baldwin</surname></persName>
		</author>
		<idno type="DOI">10.4088/JCP.18com12123</idno>
	</analytic>
	<monogr>
		<title level="j">J Clin Psychiatry</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">G</forename><surname>Potkin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Kane</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">U</forename><surname>Correll</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41537-019-0090-z</idno>
	</analytic>
	<monogr>
		<title level="j">Schizophrenia</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">1</biblScope>
			<date type="published" when="2020" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<monogr>
		<title level="m" type="main">Evaluation of the Cost-effectiveness of Services for</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Jin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Tappenden</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">H</forename><surname>Maccabe</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Schizophrenia in the UK Across the Entire Care Pathway in a Single Whole-Disease Model</title>
		<idno type="DOI">10.1001/jamanetworkopen.2020.5888</idno>
	</analytic>
	<monogr>
		<title level="j">JAMA Network Open</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<date type="published" when="2020" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Real-world clinical and cost-effectiveness of community clozapine initiation: mirror cohort study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Butler</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Pillinger</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Brown</surname></persName>
		</author>
		<idno type="DOI">10.1192/bjp.2022.47</idno>
	</analytic>
	<monogr>
		<title level="m">* This study demonstrates the feasibility and cost</title>
		<imprint>
			<date type="published" when="2022" />
			<biblScope unit="volume">221</biblScope>
			<biblScope unit="page" from="740" to="747" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Siskind</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Orr</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Sinha</surname></persName>
		</author>
		<idno type="DOI">10.1192/bjp.2021.61</idno>
	</analytic>
	<monogr>
		<title level="j">Br J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">220</biblScope>
			<biblScope unit="page" from="115" to="120" />
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<monogr>
		<title level="m" type="main">This important meta-analysis provides clear evidence for the high</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">*</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Clozapine as a first-or second-line treatment in schizophrenia: a systematic review and meta-analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Okhuijsen-Pfeifer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eah</forename><surname>Huijsman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Hasan</surname></persName>
		</author>
		<idno type="DOI">10.1111/acps.12954</idno>
	</analytic>
	<monogr>
		<title level="j">Acta psychiatrica Scandinavica</title>
		<imprint>
			<biblScope unit="volume">138</biblScope>
			<biblScope unit="page" from="281" to="288" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Brain-imaging studies of treatment-resistant schizophrenia: a systematic review</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Mouchlianitis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Mccutcheon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><forename type="middle">D</forename><surname>Howes</surname></persName>
		</author>
		<idno type="DOI">10.1016/S2215-0366(15)00540-4</idno>
		<ptr target="https://doi.org/10.1016/S2215-0366(15" />
	</analytic>
	<monogr>
		<title level="j">The Lancet Psychiatry</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="451" to="463" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Wada</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Noda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Iwata</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41380-022-01572-0</idno>
	</analytic>
	<monogr>
		<title level="j">Molecular Psychiatry</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="2950" to="2967" />
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<monogr>
		<title level="m" type="main">The authors provide an overview of the heterogenous pathophysiology of TRS. Pathophysiological alteration in dopaminergic, glutamatergic, and GABAergic pathways emerge as important mechanisms</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">*</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Treatment resistance in psychiatry: state of the art and new directions</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><forename type="middle">D</forename><surname>Howes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">E</forename><surname>Thase</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Pillinger</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41380-021-01200-3</idno>
	</analytic>
	<monogr>
		<title level="j">Molecular Psychiatry</title>
		<imprint>
			<date type="published" when="2021" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<monogr>
		<title level="m" type="main">highly topical summary of the mechanisms underlying treatment resistance and pseudo-resistance in mental disorders. The authors also provide clear recommendations to address current challenges in the diagnosis and therapy of treatment resistance</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>** A</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">The Group of Treatment Resistant Schizophrenias</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">J</forename><surname>Kinon</surname></persName>
		</author>
		<idno type="DOI">10.3389/fpsyt.2018.00757</idno>
	</analytic>
	<monogr>
		<title level="j">Heterogeneity in Treatment Resistant Schizophrenia (TRS). Front Psychiatry</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [(18)F]DOPA PET Study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><forename type="middle">D</forename><surname>Howes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Veronese</surname></persName>
		</author>
		<idno type="DOI">10.1038/npp.2016.258</idno>
	</analytic>
	<monogr>
		<title level="j">Neuropsychopharmacology</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="941" to="950" />
			<date type="published" when="2016-11-18" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Clozapine Reverses Dysfunction of Glutamatergic Neurons Derived From Clozapine-Responsive Schizophrenia Patients</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Hribkova</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><surname>Svoboda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Bartecku</surname></persName>
		</author>
		<idno type="DOI">10.3389/fncel.2022.830757</idno>
	</analytic>
	<monogr>
		<title level="j">Front Cell Neurosci</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Kishimoto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Hagi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Kurokawa</surname></persName>
		</author>
		<idno type="DOI">10.1016/S2215-0366(21)00039-0</idno>
		<ptr target="https://doi.org/10.1016/S2215-0366(21" />
	</analytic>
	<monogr>
		<title level="j">The Lancet Psychiatry</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="387" to="404" />
			<date type="published" when="2021" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Clinical correlates of early onset antipsychotic treatment resistance</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Fonseca De Freitas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Agbedjro</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Kadra-Scalzo</surname></persName>
		</author>
		<idno type="DOI">10.1177/02698811221132537</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Psychopharmacology</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="1226" to="1233" />
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<monogr>
		<title level="m" type="main">A Guideline and Checklist for Initiating and</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">U</forename><surname>Correll</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><surname>Agid</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Crespo-Facorro</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">** A state-of-the-art guideline for the safe and effective use of clozapine in TRS</title>
		<idno type="DOI">10.1007/s40263-022-00932-2</idno>
	</analytic>
	<monogr>
		<title level="j">CNS Drugs</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="659" to="679" />
			<date type="published" when="2022-06-27" />
		</imprint>
	</monogr>
	<note>Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia. To this end, the authors provide evidence-based checklists very suitable for routine clinical use</note>
</biblStruct>

<biblStruct xml:id="b52">
	<monogr>
		<title level="m" type="main">Second to None -Rationale, Timing, and Clinical Management of</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Qubad</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">A</forename><surname>Bittner</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<monogr>
		<title level="m" type="main">Therapeutic Advances in Psychopharmacology 2023 * A comprehensive overview of all clinical relevant aspects of clozapine use including interactions, side effect management, re-challenges and augementation strategies for poor responders</title>
		<imprint/>
	</monogr>
	<note>Clozapine Use in Schizophrenia</note>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">** A systematic review covering the most relevant side effects potentially associated with clozapine treatment</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">J</forename><surname>Gurrera</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">F</forename><surname>Gearin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Love</surname></persName>
		</author>
		<idno type="DOI">10.1111/acps.13406</idno>
		<ptr target="https://doi.org/10.1111/acps.13406" />
	</analytic>
	<monogr>
		<title level="j">Acta Psychiatrica Scandinavica</title>
		<imprint>
			<biblScope unit="volume">145</biblScope>
			<biblScope unit="page" from="423" to="441" />
			<date type="published" when="2022" />
		</imprint>
	</monogr>
	<note>Recognition and management of clozapine adverse effects: A systematic review and qualitative synthesis. The authors convincingly conclude that these side effects rarely require discontinuation of clozapine</note>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Clozapine Rechallenge After Major Adverse Effects: Clinical Guidelines Based on 259 Cases</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Manu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Lapitskaya</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Shaikh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">American Journal of Therapeutics</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Clozapine-Related Myocarditis and Rechallenge: A Case Series and Clinical Review</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">C</forename><surname>No√´l</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Powell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Burton</surname></persName>
		</author>
		<idno type="DOI">10.1097/jcp.0000000000001062</idno>
	</analytic>
	<monogr>
		<title level="j">J Clin Psychopharmacol</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="380" to="385" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<monogr>
		<title level="m" type="main">The case for clozapine treatment of schizophrenia 40</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Bittner</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft f√ºr Neuropsychopharmakologie und Pharmakopsychiatrie</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Schoretsanitis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Kane</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">U</forename><surname>Correll</surname></persName>
		</author>
		<idno type="DOI">10.4088/JCP.19cs13169</idno>
	</analytic>
	<monogr>
		<title level="j">J Clin Psychiatry</title>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope unit="page">20200519</biblScope>
			<date type="published" when="2020" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Siskind</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Siskind</forename><forename type="middle">V</forename><surname>Kisely</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename></persName>
		</author>
		<idno type="DOI">10.1177/0706743717718167</idno>
	</analytic>
	<monogr>
		<title level="j">Can J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="772" to="777" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Routine clozapine assay monitoring to improve the management of treatment-resistant schizophrenia</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Kitchen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Till</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Xavier</surname></persName>
		</author>
		<idno type="DOI">10.1192/bjb.2021.36</idno>
	</analytic>
	<monogr>
		<title level="m">* This study demonstrates that introducing routine TDM in clozapine treatment is very feasible</title>
		<imprint>
			<date type="published" when="2022" />
			<biblScope unit="volume">46</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Delayed Initiation of Clozapine Continues to Be a Substantial Clinical Concern</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">P</forename><surname>John</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ekf</forename><surname>Ko</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dominic</forename><forename type="middle">A</forename></persName>
		</author>
		<idno type="DOI">10.1177/0706743718772522</idno>
	</analytic>
	<monogr>
		<title level="j">Can J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="526" to="531" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">The clinical significance of duration of untreated psychosis: an umbrella review and random-effects meta-analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><forename type="middle">D</forename><surname>Howes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Whitehurst</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Shatalina</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">World Psychiatry</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="75" to="95" />
			<date type="published" when="2021" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<monogr>
		<title/>
		<idno type="DOI">10.1002/wps.20822</idno>
		<ptr target="https://doi.org/10.1002/wps.20822" />
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Predictors of Treatment-Resistant and Clozapine-Resistant Schizophrenia: A 12-Year Follow-up Study of First-Episode Schizophrenia-Spectrum Disorders</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Skw</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hyv</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">G</forename><surname>Honer</surname></persName>
		</author>
		<idno type="DOI">10.1093/schbul/sbaa145</idno>
		<ptr target="DOI:10.1093/schbul/sbaa145" />
	</analytic>
	<monogr>
		<title level="j">Schizophrenia Bulletin</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="485" to="494" />
			<date type="published" when="2021" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Shortening Duration of Treatment Resistance: The Next Step in the Treatment of Schizophrenia</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">L</forename><surname>Sutterland</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Van Der Pluijm</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">E</forename><surname>Becker</surname></persName>
		</author>
		<idno type="DOI">10.1093/schizbullopen/sgaa030</idno>
	</analytic>
	<monogr>
		<title level="j">Schizophrenia Bulletin Open</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<date type="published" when="2020" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Prevalence of treatment resistance and clozapine use in early intervention services</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Stokes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">L</forename><surname>Griffiths</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Jones</surname></persName>
		</author>
		<idno type="DOI">10.1192/bjo.2020.8948</idno>
	</analytic>
	<monogr>
		<title level="j">BJPsych Open</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<date type="published" when="2020" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Systematic literature review of 15 international clinical guidelines on acute and maintenance treatment with antipsychotics. Clozapine is unanimously recommended for TRS</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Correll</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Patel</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41537-021-00192-</idno>
	</analytic>
	<monogr>
		<title level="j">NPJ schizophrenia</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<date type="published" when="2022" />
		</imprint>
	</monogr>
	<note>x ** An instructive summary of 15 current international guidelines. which unanimously recommend clozapine for the treatment of TRS</note>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Utility and Barriers to Clozapine Use: A Joint Study of Clinicians&apos; Attitudes From Singapore and Hong Kong</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lee</forename><forename type="middle">J</forename></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chan</forename><surname>Skw</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Psychiatry</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page">20220518</biblScope>
			<date type="published" when="2022" />
		</imprint>
	</monogr>
	<note>DOI: 10.4088/JCP.21m14231 * This investigation adds to evidence regarding the considerable hesitancy of psychiatrists to prescribe clozapine</note>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Clozapine prescribing barriers in the management of treatment-resistant schizophrenia: A systematic review</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">I</forename><surname>Baig</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Bazargan-Hejazi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Ebrahim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Medicine</title>
		<imprint>
			<biblScope unit="page">100</biblScope>
			<date type="published" when="2021" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<monogr>
		<title level="m" type="main">* A timely review of the different obstacles for greater clozapine use emphasizing the role of prescriber-related barriers</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<monogr>
		<title level="m" type="main">Gender disparities in clozapine prescription in a cohort of treatment-resistant schizophrenia in the South London and Maudsley case register</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wellesley</forename><surname>Wesley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Kadra-Scalzo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title/>
		<idno type="DOI">10.1016/j.schres.2021.05.006</idno>
		<ptr target="https://doi.org/10.1016/j.schres.2021.05.006" />
	</analytic>
	<monogr>
		<title level="j">Schizophrenia Research</title>
		<imprint>
			<biblScope unit="volume">232</biblScope>
			<biblScope unit="page" from="68" to="76" />
			<date type="published" when="2021" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<monogr>
		<title level="m" type="main">* An important study demonstratingc that women with TRS are less likely to be prescribed clozapine than men with TRS</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">Addressing Barriers to Clozapine Underutilization: A National Effort</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">L</forename><surname>Kelly</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><surname>Freudenreich</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">A</forename><surname>Sayer</surname></persName>
		</author>
		<idno type="DOI">10.1176/appi.ps.20170016253</idno>
	</analytic>
	<monogr>
		<title level="j">Psychiatric Services</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="224" to="227" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">A Comparison of Attitudes, Comfort, and Knowledge of Clozapine Among Two Diverse Samples of US Psychiatrists</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">O</forename><surname>Cotes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">U</forename><surname>Janjua</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Broussard</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10597-021-00847-0</idno>
	</analytic>
	<monogr>
		<title level="j">Community Mental Health Journal</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="517" to="525" />
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">An evaluation of the variation and underuse of clozapine in the United Kingdom</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Whiskey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Barnard</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Oloyede</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Psychiatrica Scandinavica</title>
		<imprint>
			<biblScope unit="volume">143</biblScope>
			<biblScope unit="page" from="339" to="347" />
			<date type="published" when="2021" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<monogr>
		<title/>
		<idno type="DOI">10.1111/acps.13280</idno>
		<ptr target="https://doi.org/10.1111/acps.13280" />
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">Psychiatrists&apos; attitude towards the use of clozapine in the treatment of refractory schizophrenia: A nationwide survey</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Daod</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Krivoy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Shoval</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.psychres.2019.03.029</idno>
		<ptr target="https://doi.org/10.1016/j.psychres.2019.03.029" />
	</analytic>
	<monogr>
		<title level="j">Psychiatry Research</title>
		<imprint>
			<biblScope unit="volume">275</biblScope>
			<biblScope unit="page" from="155" to="161" />
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">Prescribers fear as a major side-effect of clozapine</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Cohen</surname></persName>
		</author>
		<idno type="DOI">10.1111/acps.12294</idno>
		<ptr target="https://doi.org/10.1111/acps.12294" />
	</analytic>
	<monogr>
		<title level="j">Acta Psychiatrica Scandinavica</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="page" from="154" to="155" />
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">Mandatory certification for clozapine prescribing</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Farooq</surname></persName>
		</author>
		<idno type="DOI">10.1192/j.eurpsy.2020.110</idno>
	</analytic>
	<monogr>
		<title level="j">European Psychiatry</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<date type="published" when="2021" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">Addressing clozapine under-prescribing and barriers to initiation: a psychiatrist, advanced practice provider, and trainee survey</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">G</forename><surname>Leung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Cusimano</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Gannon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">International Clinical Psychopharmacology</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">Patients&apos; Experiences of Clozapine for Treatment-Resistant Schizophrenia: A Systematic Review</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Parkes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Mantell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Oloyede</surname></persName>
		</author>
		<idno type="DOI">10.1093/schizbullopen/sgac042</idno>
	</analytic>
	<monogr>
		<title level="j">Schizophrenia Bulletin Open</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<monogr>
		<title level="m" type="main">This excellent review summarizes all avalailable studies on patients&apos; experience with clozapine</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">*</forename></persName>
		</author>
		<imprint/>
	</monogr>
	<note>which is consistently predominantly positive</note>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">Psychiatrists&apos; attitude towards and knowledge of clozapine treatment</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Nielsen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Dahm</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Lublin</surname></persName>
		</author>
		<idno type="DOI">10.1177/0269881108100320</idno>
	</analytic>
	<monogr>
		<title level="j">J Psychopharmacol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="965" to="971" />
			<date type="published" when="2009-01-22" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">Clozapine Treatment Is Associated With Higher Prescription Rate of Antipsychotic Monotherapy and Lower Prescription Rate of Other Concomitant Psychotropics: A Real-World Nationwide Study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Ochi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Tagata</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Hasegawa</surname></persName>
		</author>
		<idno type="DOI">10.1093/ijnp/pyac036</idno>
		<ptr target="DOI:10.1093/ijnp/pyac036" />
	</analytic>
	<monogr>
		<title level="j">International Journal of Neuropsychopharmacology</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="818" to="826" />
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b86">
	<monogr>
		<title level="m" type="main">This importanty study demonstrates that clozapine treatment leads to less polypharmacy. This is an important factor in reducing the overall side-effect burden</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">*</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">A user&apos; guide to clozapine</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Kane</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Psychiatrica Scandinavica</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="407" to="408" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b88">
	<monogr>
		<title/>
		<idno type="DOI">10.1111/j.1600-0447.2011.01711.x</idno>
		<ptr target="https://doi.org/10.1111/j.1600-0447.2011.01711.x.DOI:https://doi.org/10.1111/j.1600-" />
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">How to Make an Effective Offer of Clozapine</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Rubio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Kane</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Psychiatry</title>
		<imprint>
			<date type="published" when="2021" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b90">
	<monogr>
		<title/>
		<idno type="DOI">10.4088/JCP.21ac14000</idno>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main">Time to Support Extensive Implementation of Shared Decision Making in Psychiatry</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Zisman-Ilani</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Roth</forename><forename type="middle">Rm</forename><surname>Mistler</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">A</forename></persName>
		</author>
		<idno type="DOI">10.1001/jamapsychiatry.2021.2247</idno>
	</analytic>
	<monogr>
		<title level="j">JAMA Psychiatry</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="page" from="1183" to="1184" />
			<date type="published" when="2021" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main">* A very timely editorial advocating the routine use of shared decision-making in patients with severe mental illness. The authors also discuss important 65</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">A</forename><surname>Keepers</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">J</forename><surname>Fochtmann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Anzia</surname></persName>
		</author>
		<idno type="DOI">10.1176/appi.ajp.2020.177901</idno>
		<ptr target="DOI:10.1176/appi.ajp.2020.177901" />
	</analytic>
	<monogr>
		<title level="j">Am J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">177</biblScope>
			<biblScope unit="page" from="868" to="872" />
			<date type="published" when="2020" />
		</imprint>
	</monogr>
	<note>The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia</note>
</biblStruct>

<biblStruct xml:id="b93">
	<monogr>
		<title level="m" type="main">Optimizing clozapine through clinical decision making. Acta</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">R</forename><surname>Falzer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">M</forename><surname>Garman</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<title/>
		<idno type="DOI">10.1111/j.1600-0447.2012.01863.x</idno>
		<ptr target="https://doi.org/10.1111/j.1600-0447.2012.01863.x.DOI:https://doi.org/10.1111/j.1600-0447.2012.01863.x67" />
	</analytic>
	<monogr>
		<title level="j">Psychiatrica Scandinavica</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page" from="47" to="58" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b95">
	<analytic>
		<title level="a" type="main">Increasing Clozapine Use Through Residency Training: Knowledge and Clinical Proficiency Are Necessary but Not Sufficient</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">R</forename><surname>Falzer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">M</forename><surname>Garman</surname></persName>
		</author>
		<idno type="DOI">10.1007/s40596-013-0030-6</idno>
	</analytic>
	<monogr>
		<title level="j">Academic Psychiatry</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="109" to="110" />
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main">Systematic review and meta-analysis of factors that help or hinder treatment decision-making capacity in psychosis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Larkin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Hutton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The British Journal of Psychiatry</title>
		<imprint>
			<biblScope unit="volume">211</biblScope>
			<biblScope unit="page" from="205" to="215" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b97">
	<analytic>
		<title level="a" type="main">Neuropsychological differences between treatmentresistant and treatment-responsive schizophrenia: a meta-analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Millgate</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><surname>Hide</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">M</forename><surname>Lawrie</surname></persName>
		</author>
		<idno type="DOI">10.1017/S0033291721004128</idno>
	</analytic>
	<monogr>
		<title level="j">Psychological Medicine</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="1" to="13" />
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b98">
	<analytic>
		<title level="a" type="main">Subtle ways of stigmatization among professionals: The subjective experience of consumers and their family members</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Amsalem</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Hasson-Ohayon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Gothelf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Psychiatric rehabilitation journal</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page">163</biblScope>
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b99">
	<analytic>
		<title level="a" type="main">Schizophrenia stigma in mental health professionals and associated factors: A systematic review</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K-M</forename><surname>Valery</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Prouteau</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.psychres.2020.113068</idno>
		<ptr target="https://doi.org/10.1016/j.psychres.2020.113068" />
	</analytic>
	<monogr>
		<title level="j">Psychiatry Research</title>
		<imprint>
			<biblScope unit="volume">290</biblScope>
			<biblScope unit="page">113068</biblScope>
			<date type="published" when="2020" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b100">
	<analytic>
		<title level="a" type="main">Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia -Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Wagner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Kane</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">U</forename><surname>Correll</surname></persName>
		</author>
		<idno type="DOI">10.1093/schbul/sbaa060</idno>
	</analytic>
	<monogr>
		<title level="j">Schizophr Bull</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<date type="published" when="2020" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b101">
	<analytic>
		<title level="a" type="main">The practical management of refractory schizophrenia--the Maudsley Treatment REview and Assessment Team service approach</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Beck</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Mccutcheon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">A</forename><surname>Bloomfield</surname></persName>
		</author>
		<idno type="DOI">10.1111/acps.12327</idno>
	</analytic>
	<monogr>
		<title level="j">Acta Psychiatr Scand</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="page" from="427" to="438" />
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b102">
	<analytic>
		<title level="a" type="main">Clozapine Underutilization in the Treatment of Schizophrenia: How Can Clozapine Prescription Rates Be Improved?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">P</forename><surname>Bogers</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">F</forename><surname>Schulte</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Van Dijk</surname></persName>
		</author>
		<idno type="DOI">10.1097/jcp.0000000000000478</idno>
	</analytic>
	<monogr>
		<title level="j">J Clin Psychopharmacol</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="109" to="111" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b103">
	<analytic>
		<title level="a" type="main">The muscarinic system, cognition and schizophrenia</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">P</forename><surname>Carruthers</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">T</forename><surname>Gurvich</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">L</forename><surname>Rossell</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.neubiorev.2015.05.011</idno>
	</analytic>
	<monogr>
		<title level="j">Neurosci Biobehav Rev</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="393" to="402" />
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b104">
	<analytic>
		<title level="a" type="main">Relegating Psychosis: Blood Work and &quot;Routine Connection&quot; in the Clozapine Clinic</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jeh</forename><surname>Brown</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11013-019-09653-6</idno>
	</analytic>
	<monogr>
		<title level="j">Culture, Medicine, and Psychiatry</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="263" to="285" />
			<date type="published" when="2020" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b105">
	<analytic>
		<title level="a" type="main">Clozapine haematological monitoring for neutropenia: a global perspective</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Oloyede</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Blackman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Whiskey</surname></persName>
		</author>
		<idno type="DOI">10.1017/s204579602200066x</idno>
	</analytic>
	<monogr>
		<title level="j">Epidemiol Psychiatr Sci</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b106">
	<analytic>
		<title level="a" type="main">A predictor model of treatment resistance in schizophrenia using data from electronic health records</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Kadra-Scalzo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Fonseca De Freitas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Agbedjro</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0274864**</idno>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b107">
	<analytic>
		<title level="a" type="main">Predicting treatment resistance from first-episode psychosis using routinely collected clinical information</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">F</forename><surname>Osimo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">I</forename><surname>Perry</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Mallikarjun</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature Mental Health</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="25" to="35" />
			<date type="published" when="2023" />
			<publisher>DOI</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b108">
	<analytic>
		<title level="a" type="main">Gamma-aminobutyric acid (GABA) levels in the midcingulate cortex and clozapine response in patients with treatment-resistant schizophrenia: A proton magnetic resonance spectroscopy (1H-MRS) study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">D</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Pinz√≥n-Espinosa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Blouzard</surname></persName>
		</author>
		<idno type="DOI">10.1111/pcn.13463</idno>
		<ptr target="https://doi.org/10.1111/pcn.13463" />
	</analytic>
	<monogr>
		<title level="j">Psychiatry and Clinical Neurosciences</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="page" from="587" to="594" />
			<date type="published" when="2022" />
		</imprint>
	</monogr>
	<note>JAMA Psychiatry</note>
</biblStruct>

<biblStruct xml:id="b109">
	<analytic>
		<title level="a" type="main">Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Vallianatou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Whiskey</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41537-022-00232-0</idno>
	</analytic>
	<monogr>
		<title level="j">Schizophrenia</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">21</biblScope>
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b110">
	<analytic>
		<title level="a" type="main">* This meta analysis on risk factors for myocarditis, one of the most important side effects of clozapine, provides important guidance for clinical decision-making</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Vickers</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Ramineni</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Malacova</surname></persName>
		</author>
		<idno type="DOI">10.1111/acps.13398</idno>
	</analytic>
	<monogr>
		<title level="j">Acta Psychiatr Scand</title>
		<imprint>
			<biblScope unit="volume">145</biblScope>
			<date type="published" when="2022" />
		</imprint>
	</monogr>
	<note>Risk factors for clozapine-induced myocarditis and cardiomyopathy: A systematic review and meta-analysis</note>
</biblStruct>

<biblStruct xml:id="b111">
	<monogr>
		<title level="m" type="main">The case for clozapine treatment of schizophrenia 84</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Bittner</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>An International Adult Guideline for Making</note>
</biblStruct>

<biblStruct xml:id="b112">
	<analytic>
		<title level="a" type="main">Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels</title>
		<idno type="DOI">10.1055/a-1625-6388</idno>
	</analytic>
	<monogr>
		<title level="j">Pharmacopsychiatry</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<date type="published" when="2022" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b113">
	<monogr>
		<title level="m" type="main">Using a precision medicine approacht, this expert guideline proposes differential clozapine dosing and tritraion schemes based on factors including ethnicity, gender, and estimated clozapine metabolism status</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b114">
	<analytic>
		<title level="a" type="main">Best Practices for Starting Clozapine in Patients With Schizophrenia: How to Switch From the Prior Antipsychotic(s)</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Schoretsanitis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>De Leon</surname></persName>
		</author>
		<idno type="DOI">10.4088/JCP.22ac14500</idno>
	</analytic>
	<monogr>
		<title level="j">J Clin Psychiatry</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page">20220704</biblScope>
			<date type="published" when="2022" />
		</imprint>
	</monogr>
	<note>* The authors provide detailed advice on switching to clozapine from prior antipsychotics. focusing on compounds for which particular caution is warranted</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
